Product

Portfolio Intelligence Portside Congress trades Super-investors Economic calendar Earnings calendar Pricing

Company

About FAQs Contact Create account

Legal

Privacy Terms Portside rules

MYGN

Myriad Genetics INC

COMMON STOCK · NASDAQ

Price and daily changeSign in

Earnings4 Nov 2026

52-week rangeSign in

Loading evidence for MYGN

Day range

Market cap: Sign in
Volume: Sign in
Beta: Sign in
Shares float: Sign in
Short interest: 8.20%
P/E (fwd): Sign in
PEG (fwd): Sign in
Rev growth (fwd): Sign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Create free account

Overview Statistics Statements Dividends🔒Momentum🔒Quant🔒Fair Value🔒Earnings Analysts🔒Insiders Smart Money Options🔒Insights🔒

Trading information

Beta: Sign in
Shares outstandingAs of 2026-02-19 · filed common shares: 93.50M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers as a group, DEF 14A filed 2026-04-14: 1.98%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 8.20%
Short ratioDays to cover, as published by FINRA: 5.00
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 44.90%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 33.20%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Avg volume (3 months)

Profitability

Gross marginTTM to Jun 26: 68.83%
Operating marginTTM to Jun 26: -12.22%
Net margin: —
EBITDA marginFY Dec 25: -40.45%
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -32.57%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -17.13%

Growth

Revenue growth (annual YoY): -1.56%
Revenue growth (latest qtr YoY): -10.51%
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

-1.20

EPS (fwd)

Financial health

Cash & equivalentsas of Jun 26: $115.20M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $120.70M
Debt / equityas of Jun 26: 39.72%
Current ratioas of Jun 26: 2.21
Quick ratio(Cash + marketable securities + receivables) ÷ current liabilities, as of Dec 25: 1.98
Operating cash flowTTM to Mar 26: $2.40M
Free cash flowUnadjusted FCF = CFO − capex · FY Dec 25: -$13.80M
TTM revenue / diluted shareDiluted, TTM to Jun 26: 8.60

MYGN stock Statistics — Myriad Genetics INC filings, insiders & smart money · Instaport